Clinical trials: Kidney Disease
Kidney Disease
Role of Nox2 in CNI-induced Renal Fibrosis
Calcineurin Inhibitors (CNI) are drugs used to suppress the immune system when a person has a solid organ transplant. Although these drugs keep the transplanted organ from being rejected they are toxic to kidneys, or nephrotoxic.
- Trial name
- Nox2 (NCT01674465)
- Testing
- Hypoxyprobe-1
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Wisconsin, Madison
IGA Nephropathy
Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy
TO ASSESS THE EFFICACY OF THE RENIN ANGIOTENSIN SYSTEM PLUS STEROIDS TO DECREASE THE AMOUNT OF PROTEINURIA IN IGA NEPHROPATHY
- Trial name
- NCT00367562
- Testing
- ENALAPRIL VALSARTAN METHYLPREDNISONE
- Where
- Argentina
- Volunteers
- 20 people
- Sponsor
- Hospital Britanico
Chronic Kidney Disease, AST-120
Effect of An Oral Absorbent AST-120 in Late-stage Chronic Kidney Disease (CKD) Patients.
Recent research work has directed especial attention toward a distinct group of uremic retension molecules, called "protein-bound uremic toxins". The prototypes of this group of uremic toxins are indoxyl sulfate and p-cresol.
- Trial name
- NCT01681303
- Testing
- AST-120
- Where
- Taiwan
- Volunteers
- 51 people
- Sponsor
- Chang Gung Memorial Hospital
Renal Cell Carcinoma
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
This study is designed to explore the molecular modulatory effect of Sunitinib when given in a neoadjuvant setting prior to radical or partial nephrectomy.
- Trial name
- NCT01070186
- Testing
- Sunitinib, Tumor biopsy, Nephrectomy
- Sponsor
- Jonsson Comprehensive Cancer Center
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
End Stage Renal Disease
Mid-HDF Randomized Controlled Study on Outcome
The purpose of this study is to determine whether mid-dilution hemodiafiltration is effective in the reduction of the crude mortality risk in patients who have been undergoing renal replacement treatment for less than 1 year.
- Trial name
- MILESTONE (NCT01693354)
- Testing
- Mid-dilution HDF, HF dialysis
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 500 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Kidney Stones, Nephrolithiasis
FANS vs CVAC for Medium to Large Stones
Improvements in ureteroscopes have led to improved stone free rates. Two new devices (FANS - Flexible and Navigable Suction) and the CVAC ureteroscope have never been compared head to head.
- Trial name
- NCT07514351
- Testing
- ureteroscopy, CVAC
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Ohio State University
Anti-p53 TCR-Gene
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Background: The p53 gene normally suppresses tumor growth, but when it is mutated, or damaged, tumors can grow unchecked. In cancers where the p53 gene has mutated, an increased level of p53(overexpression of p53) can be measured…
- Trial name
- NCT00393029
- Testing
- anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study is to evaluate the variability of several pharmacodynamic measures of kidney function, cardiovascular function, cerebral perfusion, and haemodynamics.
- Trial name
- NCT01551446
- Testing
- Bardoxolone Methyl
- Sponsor
- Biogen
Oxidative Stress Response, Hemodialysis
Effects of L-carnitine and Coenzyme Q10 Supplementation on Oxidative Stress in Tunisian Hemodialysis Patients.
The goal of this clinical trial was to learn if supplementation with L-carnitine or Coenzyme Q10 improves effectively the oxidative stress markers in adult patients undergoing chronic hemodialysis.
- Conditions
- Oxidative Stress Response, Hemodialysis, End Stage Kidney Disease (ESRD)
- Trial name
- L-car-Q10 (NCT07303088)
- Testing
- Oral administration of L-carnitine 1000 Mg, Oral administration of Coenzyme Q10 300Mg
- Where
- Tunisia
- Volunteers
- 52 people
- Sponsor
- University of Sfax
Renovascular Hypertension, Renovascular Hypertension With Renal Failure
Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.
The goal of this clinical trial is to document a beneficial effect of percutaneous transluminal renal angioplasty (PTRA) of atherosclerotic renal artery stenosis in high-risk patients selected according to the criteria used in…
- Conditions
- Renovascular Hypertension, Renovascular Hypertension With Renal Failure, Heart Failure, Renal Artery Stenosis Atherosclerotic
- Trial name
- DAN-PTRAII (NCT05834803)
- Testing
- Optimal medical therapy (OMT), Catheter-based angiography, Measurement of translesional pressure gradients
- Where
- 3 sites in Denmark
- Volunteers
- 80 people
- Sponsor
- University of Aarhus
Chronic Kidney Disease
Remission Clinic in Proteinuric Chronic Nephropathies
Most chronic kidney diseases have a progressive evolution characterized by the gradual loss of glomerular filtration rate (GFR), electrolytic imbalance, reduced erythropoietin synthesis and activation of vitamin D.
- Trial name
- NCT02721342
- Testing
- Ramipril, Irbesartan and Atorvastin
- Where
- 13 sites in Italy
- Volunteers
- 1,500 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Kidney Transplant Recipients, Liver Transplant Recipients
COVID Protection After Transplant-Immunosuppression Reduction
This study will enroll individuals who have: Completed primary series of mRNA COVID-19 vaccine, and An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine.
- Trial name
- CPAT-ISR (NCT05077254)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen
- Where
- 15 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetic Nephropathy Type 2, Type 2 Diabetes
Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status
Chronic inflammation underlies the bidirectional relationship between diabetes and periodontitis, a process that may be further exacerbated in the presence of diabetic nephropathy.
- Conditions
- Diabetic Nephropathy Type 2, Type 2 Diabetes, Periodontitis, Gingivitis
- Trial name
- NCT07498894
- Testing
- clinical periodontal measurements, serum samples, saliva samples
- Where
- Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Pamukkale University
Primary Aldosteronism
Renal Cysts and Primary Aldosteronism
During routine subtyping of confirmed primary aldosteronism by adrenal vein sampling extra plasma samples are drawn from both renal veins and from inferior vena cava.
- Trial name
- NCT05435703
- Where
- Finland
- Volunteers
- 115 people
- Sponsor
- Tampere University Hospital
Renal Failure, Chronic, Diabetic Nephropathies
Glucose in Dialysis Water in Diabetics With Chronic Renal Failure
The purposes are 1. to measure the effect of dialysis with glucose in dialysis water on blood pressure, pulse rate, plasma concentration of glucose, plasma concentrations og insulin, glucagon, growth hormone, renin, angiotensin…
- Trial name
- NCT00438503
- Testing
- Procedure
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Regional Hospital Holstebro
Locally Metastatic Malignant Neoplasm
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
This is a phase II trial that follows the completion of the phase I UCSF trial of everolimus and sorafenib for Renal Cell Carcinoma (RCC). This trial will be for patients who have not had treatment for RCC before.
- Trial name
- NCT01616186
- Testing
- Everolimus and sorafenib, Sunitinib monotherapy
- Sponsor
- Andrea Harzstark
Latent Tuberculosis Infection, End Stage Renal Disease (ESRD)
Prevalence of Latent Tuberculosis Infection Among Hemodialysis Patients
This observational cross-sectional study aims to determine the prevalence of latent tuberculosis infection (LTBI) among patients undergoing regular hemodialysis at Sohag University Hospital, using the tuberculin skin test (TST).
- Conditions
- Latent Tuberculosis Infection, End Stage Renal Disease (ESRD), Hemodialysis
- Trial name
- NCT07210970
- Testing
- Tuberculin Skin Test (TST)
- Volunteers
- 200 people
- Sponsor
- Sohag University
Renal Artery Obstruction, Kidney Disease
MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery
This study will use magnetic resonance imaging (MRI) to picture the kidney and renal arteries (arteries that supply blood to the kidney) in patients scheduled for kidney artery angiogram and angioplasty/stenting procedures.
- Trial name
- NCT00027469
- Testing
- MRI
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
- Conditions
- Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy
- Trial name
- RENEW (NCT05162066)
- Testing
- BCX9930
- Where
- 11 sites in France, Italy and 2 more
- Volunteers
- 2 people
- Sponsor
- BioCryst Pharmaceuticals